BioAtla, Inc. (BCAB) Stock Score, Valuation & Financial Research
BioAtla, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 18/100.
Quick answer for BCAB
BioAtla, Inc. currently has a Wall Street Score of 18/100. The stored market price is $1.74. Its financial score is 1/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What BioAtla, Inc. does
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cance
BCAB financial snapshot
- Wall Street Score:
- 18/100
- Current price:
- $1.74
- Market capitalization:
- $2.9M
- Revenue:
- $8.5M
- Net income:
- $-31.5M
- Free cash flow:
- $-48.2M
- Cash:
- $1.5M
- Total debt:
- $5.9M
- EPS:
- -25.45
- Financial score:
- 1/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is +3.3%.
- Free cash flow is $-48.2M, showing cash burn in the current stored period.
- The balance sheet shows $1.5M of cash versus $5.9M of total debt, so leverage deserves attention.
- The current research record carries a corporate distress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 1/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BCAB
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.